Tilray has imported health-related cannabis into the US from Canada in assistance of a new clinical trial.
The trial will test the security and efficacy of health-related cannabis in treating breast cancer individuals suffering from taxane-induced peripheral neuropathy (TIPN) secondary to remedy with paclitaxel or docetaxel.
Tilray’s clinical trial on cannabis is the initially human study testing the efficiency of health-related cannabis to treat TIPN.
The initially-of-its-type trial will test the efficacy of cannabis as a remedy for TIPN, which impacts roughly 67% of females undergoing breast cancer remedy.
Tilray International Patient Study and Access vice-president Philippe Lucas mentioned: “Tilray is committed to advancing cannabis investigation via its assistance of clinical trials about the planet as we continue to improve our understanding of the prospective positive aspects of health-related cannabis.”
The study is led by Columbia University Irving Healthcare Center (CUIMC) Psychiatry professor Diana Martinez and CUIMC neurobiology professor Margaret Haney.
Tilray noted that the clinical trial will be a randomised, placebo-controlled study. Half of the subjects will obtain an investigational item containing a mixture of THC and CBD, though the other half of the participants will obtain a item with no active cannabinoids.
The trial will see participants becoming treated twice every day for eight weeks. Patient recruitment is underway for the study.
Margaret Haney mentioned: “There is a crucial need to have for randomised controlled clinical research to test the efficacy of cannabis in individuals.
“There is fascinating preclinical proof displaying that THC and CBD drastically lessen TIPN, and our study will be the initially to test this in a effectively-powered clinical trial.”
Regardless of the lack of productive remedy for TIPN, research evaluating the use of health-related cannabis to treat paclitaxel-induced neuropathic discomfort in mice have shown good final results.
In September 2016, Tilray and the University of British Columbia started patient enrolment in Canada’s initially Phase II clinical trial of health-related cannabis to treat post-traumatic pressure disorder (PTSD).